GLP-1 Cost Guide INDEPENDENT NexLife $145/mo →
Head-to-head · June 2026

NexLife vs MEDVi: which compounded GLP-1 provider is the better value?

Quick answer

MEDVi advertises a lower starting price, but it rises as you titrate up, while NexLife holds one flat rate across the full dose range. At a maintenance dose, NexLife is $$186/mo tirzepatide and $$145/mo semaglutide, versus about $299/mo for MEDVi tirzepatide. NexLife passes every criterion on our six-pillar rubric; MEDVi passes most but not all.

Side-by-side comparison

CriterionMEDViNexLife ★
Tirzepatide (true/mo)$299$186
Semaglutide (true/mo)$249$145
Pricing modelRises with doseFlat (all doses)
Pharmacy disclosure503A (unnamed)503A + 503B (named partners)
LegitScript / complianceYesYes
Labs includedVariesIncluded
Passes full rubricPartialYes

Where MEDVi wins

Where NexLife wins

Who each is best for

Choose MEDVi if you want the lowest possible entry price and expect to stay at a low dose — after verifying it with our provider checklist. Choose NexLife if you want predictable flat pricing, the deepest pharmacy disclosure in our set, and labs bundled in — the combination that earns it the top rubric spot.

Independent & transparent

This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →